AMBS
AMARANTUS BIOSCIENCE HLDG
stock OTC

amarantus bioscience holdings (otcqb: ambs) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. ambs owns the rights to engineered skin substitute program, a regenerative medicine-based approach for treating severe burns with full thickness autologous skin grown in tissue culture. ess is entering phase 2 clinical studies under a crada agreement with the us army, and is also preparing a pivotal development program for rare pediatric disease giant congenital melanocytic nevi. ambs' also has licensing rights to eltoprazine, a phase 2b-ready small molecule indicated for parkinson's disease levodopa-induced dyskinesia, adult adhd and alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor and is developing manf-based products as treatments for brain and ophthalmic disorders. ambs' diagnostics division